Increased staining of SMYD2 has been observed in ovarian and cervical cancers, however its involvement in ovarian cancer in terms of histone methyltransferase activity, or its ability to methylate non-histone proteins such as PARP1, remains unclear [68]. Here, PRDM9 is linked to ovarian cancer.